3rd Quarter - Report

AMERICAN SOCIETY OF HEMATOLOGY for AMERICAN SOCIETY OF HEMATOLOGY

Firm
Client
Income
—
Expenses
$100,000
Expense method
A: Lobbying Disclosure Act definitions

What was lobbied

5 issue areas, each in the filer's own words, with who lobbied on it and where.

Budget/Appropriations BUD

Public health program funding Federal research funding Advanced Research Projects Agency for Health (ARPA-H) Impact of restructuring and reorganization of federal public health and research agencies FY 2027 NIH funding FY 2027 AHRQ funding FY 2027 CDC funding FY 2027 funding for CDC Sickle Cell Data Collection program FY 2027 funding for HRSA Sickle Cell Disease Treatment Demonstration program and Sickle Cell Disease Newborn Screening program FY 2027 funding for Defense Health Research Programs, including the Congressionally Directed Medical Research Programs (CDMRP) FY 2027 Department of Veterans Affairs research funding FY 2027 funding for Pediatric Specialty Loan Repayment Program Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2027 (H.R.9260) FY2027 Continuing Appropriations Act (through 12/04/2026)(H.R. 9770) FY2027 Continuing Appropriations and Extensions Act (through 12/11/2026)(H.R. 6500) OMB proposed Regulation for Federal Financial Assistance (OMB-2026-0034)

LobbyistCovered position, as disclosed
TRACY BECKER ROADES —
STEPHANIE ANN KAPLAN —
SUZANNE LEOUS —

Contacted: Food & Drug Administration (FDA); Centers For Disease Control & Prevention (CDC); Health & Human Services, Dept of (HHS); Veterans Affairs, Dept of (VA); HOUSE OF REPRESENTATIVES; Health Resources & Services Administration (HRSA); Office of Management & Budget (OMB); Office of Science & Technology Policy (OSTP); Defense, Dept of (DOD); SENATE; Agency for Healthcare Research & Quality (AHRQ); Natl Institutes of Health (NIH)

Bills named: H.R. 9770 (119th), H.R. 6500 (119th), H.R. 9260 (119th)

Medical/Disease Research/Clinical Labs MED

Sickle cell disease/trait issues Hematology/oncology treatment issues Hematology/oncology drug research and approval issues General hematology public health and research issues Issues impacting laboratory testing and pediatric reference intervals (PRIs) Clinical trials regulations and coverage Issues impacting drug shortages FDA guidance impacting hematology Impact of restructuring and reorganization of federal public health and research agencies Issues related to vaccines and immunization practices for individuals with hematologic disorders OMB proposed Regulation for Federal Financial Assistance (OMB-2026-0034) Clinical Trial Modernization Act (H.R. 3521 / S. 4440)

LobbyistCovered position, as disclosed
TRACY BECKER ROADES —
STEPHANIE ANN KAPLAN —
SUZANNE LEOUS —

Contacted: Food & Drug Administration (FDA); Health & Human Services, Dept of (HHS); President of the U.S.; Centers For Medicare and Medicaid Services (CMS); Natl Institutes of Health (NIH); HOUSE OF REPRESENTATIVES; Defense, Dept of (DOD); Office of Management & Budget (OMB); SENATE; Centers For Disease Control & Prevention (CDC); Office of Science & Technology Policy (OSTP); White House Office

Bills named: S. 4440 (119th), H.R. 3521 (119th)

Medicare/Medicaid MMM

Coverage of blood transfusions under Medicare hospice benefit Medicare physician reimbursement issues CMS national coverage determinations for autologous stem cell transplantation for multiple myeloma Medicaid coverage for sickle cell disease Issues related to telehealth and extension of telehealth flexibilities Sickle cell disease/trait issues, including coverage for cell and gene therapies Prior authorization Implementation of the Inflation Reduction Act of 2022 (P.L. 117-169) Dental coverage for Medicare beneficiaries Sickle cell disease quality measures Issues impacting drug shortages Access to safe and effective vaccines Issues related to CAR-T/cellular and gene therapies Local Coverage Decisions for hematopoietic stem cell transplantation (HSCT) for lymphoma Local Coverage Decisions for next generation sequencing Medicare Patient Access and Practice Stabilization Act of 2025 (H.R. 879) Issues related to Social Security Administration disability evaluations for sickle cell disease Impact of Medicaid funding cuts on hematology Medicare codes for Chronic Care Management (CCM) and Principal Care Management (PCM) Implementation of One Big Beautiful Bill Act (Public Law No. 119-21) Community engagement requirements of One Big Beautiful Bill Act (Public Law No. 119-21) Sickle Cell Disease Comprehensive Care Act (S. 721 / H.R. 5178) Improving Access to Transfusion Care for Hospice Patients Act (S. 1936 / H.R. 9703) Improving Seniors Timely Access to Care Act (H.R. 3514 / S. 1816) CONNECT for Health Act (H.R. 4206 / S. 1261)

LobbyistCovered position, as disclosed
TRACY BECKER ROADES —
STEPHANIE ANN KAPLAN —
SUZANNE LEOUS —

Contacted: Social Security Administration (SSA); SENATE; Centers For Medicare and Medicaid Services (CMS); Health & Human Services, Dept of (HHS); Centers For Disease Control & Prevention (CDC); Food & Drug Administration (FDA); HOUSE OF REPRESENTATIVES

Bills named: S. 721 (119th), S. 1936 (119th), H.R. 9703 (119th), H.R. 879 (119th), S. 1816 (119th), H.R. 3514 (119th), H.R. 4206 (119th), S. 1261 (119th), H.R. 5178 (119th)

Health Issues HCR

Hematology/oncology drug research and approval issues Clinical trials regulations and coverage Issues impacting coverage for hematologic diseases and conditions Implementation of No Surprises Act (P.L. 116-260) Sickle cell disease/trait issues Issues related to maternal health care and hematology Issues related to healthcare workforce Issues impacting drug shortages Sickle cell disease quality measures FDA guidance impacting hematology Access to safe and effective vaccines Impact of restructuring and reorganization of federal public health and research agencies Issues related to H-1B visas for physician workforce Sickle Cell Disease Comprehensive Care Act (S. 721 / H.R. 5178) Implementation of One Big Beautiful Bill Act (Public Law No. 119-21) Improving Access to Transfusion Care for Hospice Patients Act (S. 1936) Improving Seniors Timely Access to Care Act (H.R. 3514 / S. 1816) CONNECT for Health Act (H.R. 4206 / S. 1261) Sickle Cell Care Expansion Act of 2026 (S. 5489) Sickle Cell Disease Treatment Centers Act of 2026 (S. 5488) Resolutions expressing support for the designation of September 2026 as "Sickle Cell Disease Awareness Month" (H.Res. 1577 / S.Res. 940)

LobbyistCovered position, as disclosed
TRACY BECKER ROADES —
STEPHANIE ANN KAPLAN —
SUZANNE LEOUS —

Contacted: Health & Human Services, Dept of (HHS); HOUSE OF REPRESENTATIVES; Centers For Disease Control & Prevention (CDC); Natl Institutes of Health (NIH); Food & Drug Administration (FDA); SENATE; Centers For Medicare and Medicaid Services (CMS); Homeland Security, Dept of (DHS)

Bills named: S. 1261 (119th), S. 1936 (119th), S. 721 (119th), H.R. 4206 (119th), H.R. 3514 (119th), H.Res. 1577 (119th), S. 1816 (119th), S.Res. 940 (119th), S. 5488 (119th), H.R. 5178 (119th), S. 5489 (119th)

Immigration IMM

H-1B visa fees and exemptions for physicians

LobbyistCovered position, as disclosed
SUZANNE LEOUS —

Contacted: Homeland Security, Dept of (DHS)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.